biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Mar 05, 2019 1:15pm

116 Views

Post# 29444571

RE:RE:RE:BioBoss Interview

From the recent xB3 Medimmune paper, reference 21 (unpublished, in revision) is cited as describing the identification of the 12 amino acid Mtf-pep. "Eyford BA, Abraham T, Munro L, et al. A peptide vector delivers siRNA across the blood-brain barrier resulting in attenuation of ischemic stroke. In revision. Nature Biomed Eng." It was in unpublished and in revision at the time. Digitel mentioned Science. Both Nature and Science are great. Either on is fine! xB3 meets siRNA!

BDAZ

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity